CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Christopher Wai Kei Lam
Endocrinol Metab. 2021;36(2):279-295.   Published online April 19, 2021
DOI: https://doi.org/10.3803/EnM.2021.964

Excel Download

Homozyous familial hypercholesterolemia (HOFH): Pause prior to prescribing pricey PCSK9 inhibitors !
Atherosclerosis. 2020;315:e209   Crossref logo
Link1 Link2

Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial Hypercholesterolemia
Progress in Cardiovascular Diseases. 2016;59(2):165-171   Crossref logo
Link1 Link2

Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia
Journal of Clinical Lipidology. 2020;14(4):542   Crossref logo
Link1 Link2

Features of first patients treated with PCSK9 inhibitors in a specific lipid unit and effectiveness on lipid profile in familial hypercholesterolemia
Atherosclerosis. 2017;263:e239   Crossref logo
Link1 Link2

PCSK9: the Critical Role of Familial Hypercholesterolemia from Discovery to Benefit for all
Cardiovascular Drugs and Therapy. 2016;30(5):427-431   Crossref logo
Link1 Link2 Link3

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Endocrinology and Metabolism. 2021;36(2):279-295   Crossref logo
Link1 Link2 Link3

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Atherosclerosis. 2017;256:134-145   Crossref logo
Link1 Link2

Differential Responses to the PCSK9 Inhibitors, Evolocumab and Alirocumab, in a Patient with Heterozygous Familial Hypercholesterolemia: A Case Report
Journal of Clinical Lipidology. 2018;12(2):558-559   Crossref logo
Link1 Link2

Perceptions and Barriers on the Use of PCSK9 Inhibitors in Heterozygous Familial Hypercholesterolemia
Journal of Clinical Lipidology. 2020;14(4):586-587   Crossref logo
Link1 Link2

PCSK9 Inhibitors for Familial Hypercholesterolemia
The Journal for Nurse Practitioners. 2016;12(8):577-578   Crossref logo
Link1 Link2